Predictive oncology stock.

predictive oncology inc. certificate of designation of preferences, rights and limitations of. series e convertible preferred stock pursuant to section 151 of the. delaware general corporation law . effective june 13, 2019 .

Predictive oncology stock. Things To Know About Predictive oncology stock.

Predictive Oncology Inc. (NASDAQ:POAI – Get Free Report)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.98 and traded as low as $3.11. Predictive Oncology shares last traded at $3.11, with a volume of 20,587 shares. Predictive Oncology Price Performance The stock […]Raymond Vennare POAI stock SEC Form 4 insiders trading. Raymond has made over 1 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently Raymond bought 5,000 units of POAI stock worth $2,600 on 2 December 2022.. The largest trade Raymond's ever made was buying 5,000 units …Assess the Predictive Oncology stock price estimates. View analyst opinion as to whether the stock is a strong buy, strong sell or hold, based on analyst 12-Month POAI price targets.Press Releases. Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update. Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital. Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 2023.

Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to …Predictive Oncology. POAI. $3.09 ... as of November 29 4:00:00 PM EST. Predictive Oncology (POAI) Stock Price Performance. Predictive Oncology (POAI) Stock Key Data. Summary Additional Data ...

The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) were offered by the Company in the registered direct offerings pursuant to ...

Predictive Oncology has a market capitalisation of US$21m and burnt through US$13m last year, which is 64% of the company's market value. Given how large that cash burn is, relative to the market ...Predictive Oncology (Nasdaq:POAI) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Healthcare Predictive Oncology …The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) were offered by the Company in the registered direct offerings pursuant to ...Nov 18, 2023 · Predictive Oncology Inc. (NASDAQ:POAI – Get Free Report)’s stock price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.98 and traded as low as $3.11. Predictive Oncology shares last traded at $3.11, with a volume of 20,587 shares. Predictive Oncology Price Performance The stock […]

On May 13, 2022, Predictive Oncology Inc. (the "Company") received a letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the bid price for the Company's common stock had closed below $1.00 per share for 30 consecutive business days, and that the Company was therefore not in ...

Predictive Oncology (POAI) stock price prediction is 4.6898425267473 USD. The Predictive Oncology stock forecast is 4.6898425267473 USD for 2024 November 29 ...

Predictive Oncology (NASDAQ:POAI) on Thursday said it would effect a 1-for-20 reverse stock split.The stock split will become effective on April 24. "The reverse stock split is primarily intended ...Latest company newsPredictive Oncology forms a strategic partnership that has the potential to revolutionize the field of radiation oncology. Digital newsroomLinks to …What's Thomas Goldrick's mailing address? Thomas's mailing address filed with the SEC is 2915 COMMERS DRIVE, SUITE 900, , EAGAN, MN, 55121.Predictive Oncology Inc stock performance at a glance. Check Predictive Oncology Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. Predictive Oncology Inc stock performance at a glance. Check Predictive Oncology Inc’s past financial performance, like revenue or net income, plus the top level summary of its …

Predictive Oncology (NASDAQ: POAI) is an early-stage AI pharma stock with a differentiated business model.The company owns a biorepository of tumor samples, a lab and a good manufacturing practice ...Bank of America says this under-the-radar oncology stock can rally 180%. Published Fri, Aug 11 202311:35 AM EDT Updated Fri, Aug 11 202312:46 PM EDT. Pia Singh @pia_singh_.Nov 14, 2023 · Predictive Oncology recorded revenue of $715,056 in the third quarter of 2023, compared to $455,827 for the comparable period in 2022. The increase in revenues related primarily to higher sales of ... Real-time quotes, advanced visualizations, historical statements, and much more. Selling, General and Administrative Excl. Other. POAI - Predictive Oncology Inc - Stock screener for investors and traders, financial visualizations.Leading-edge solution. Predictive Oncology has launched a breakthrough solution at a pivotal time in drug discovery that enables pharmaceutical and biotech companies to expedite drug development and speed time to market. The company’s novel platform technology valued at $400M+ has the power to impact a billion-dollar biopharmaceutical ...The Price to Sales ratio or P/S is calculated as price divided by sales. After the P/E ratio, it's one of the most common valuation metrics. If the P/S ratio is 1, that means you're paying $1 for ...

PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital. The objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models …

4 analysts have issued 12 month price targets for Ikena Oncology's stock. Their IKNA share price targets range from $11.00 to $13.00. On average, they expect the company's share price to reach $11.67 in the next twelve months. This suggests a possible upside of 677.8% from the stock's current price.December 01, 2021 at 08:31 am EST. EAGAN, Minn., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology, (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, today announced the acquisition of zPREDICTA, a company pioneering tumor-specific in vitro 3D cell culture models ...Insiders trading at Predictive Oncology. Over the last 4 years, insiders at Predictive Oncology have traded over $30,944 worth of Predictive Oncology stock and bought 417,770 units worth $148,589 . The most active insiders traders include Carl I. Schwartz, J Melville Engle, and Charles Lee Sr Nuzum.On average, Predictive …Predictive Oncology : This medical AI innovator has plenty of potential. Duos Technologies ( DUOT ): Duos is a rising tech player that has just surpassed its penny stock status.The Predictive Oncology stock forecast is 4.3910063584427 USD for 2024 November 25, Monday; and 14.588 USD for 2028 November 25, Saturday with technical analysis. Predictive Oncology (POAI) stock price prediction is 4.3910063584427 USD.Predictive Oncology (POAI) Gets a Buy Rating from H.C. Wainwright. H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Predictive Oncology (POAI – Research Report) today and set a price target of $5.00. The company's shares closed last Thursday at $1.13. According to TipRanks.com, Bernardino is a 5-star analyst with an ...Oct 15, 2020 · The Predictive Oncology stock forecast is 4.3910063584427 USD for 2024 November 25, Monday; and 14.588 USD for 2028 November 25, Saturday with technical analysis. Predictive Oncology (POAI) stock price prediction is 4.3910063584427 USD. The estimated Net Worth of Carl I. Schwartz is at least 4.75 百万$ dollars as of 22 October 2020. Dr Schwartz owns over 640 units of Predictive Oncology stock worth over 4,318,394$ and over the last 7 years he sold POAI stock worth over 544$. In addition, he makes 433,000$ as CEO & Director at Predictive Oncology.Nov 27, 2023 · The Price to Sales ratio or P/S is calculated as price divided by sales. After the P/E ratio, it's one of the most common valuation metrics. If the P/S ratio is 1, that means you're paying $1 for ... Real-time quotes, advanced visualizations, historical statements, and much more. Selling, General and Administrative Excl. Other. POAI - Predictive Oncology Inc - Stock screener for investors and traders, financial visualizations.

Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, …

Your vote is important and easy to cast. Vote Now! Please enter your control number to view/cast your vote. Control Number. Log In ...

Their ZOM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 3,421.1% from the stock's current price. View analysts price targets for ZOM or view top-rated stocks among Wall Street analysts.Press Releases. Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update. Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital. Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 2023.The estimated Net Worth of J Melville Engle is at least $987 Thousand dollars as of 24 May 2022. Mr Engle owns over 159,500 units of Predictive Oncology stock worth over $984,422 and over the last 14 years he sold POAI stock worth over $0. In addition, he makes $3,000 as Chairman & CEO at Predictive Oncology.Feb 24, 2021 · Predictive Oncology includes various subsidiaries in the drug development and formulation space, as well as a legacy medical device business generating revenues, but this article focuses on their ... The shares of common stock described above (but not the warrants or the shares of common stock underlying the warrants) were offered by the Company in the registered direct offerings pursuant to ...Predictive Oncology (Nasdaq:POAI) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Healthcare Predictive Oncology …Latest company newsPredictive Oncology forms a strategic partnership that has the potential to revolutionize the field of radiation oncology. Digital newsroomLinks to …Here are three artificial intelligence stocks that could be acquired. SoundHound ( AI ): The company is exposed to a $500 million a year opportunity with autos and restaurants. Predictive Oncology ...Assess the Predictive Oncology stock price estimates. View analyst opinion as to whether the stock is a strong buy, strong sell or hold, based on analyst 12-Month POAI price targets.

Predictive Oncology includes various subsidiaries in the drug development and formulation space, as well as a legacy medical device business generating revenues, but this article focuses on their ...On average, Predictive Oncology executives and independent directors trade stock every 71 days with the average trade being worth of $99,350. The most recent stock trade was executed by Robert L Myers on 25 September 2023, trading 1,667 units of POAI stock currently worth $5,334.The estimated Net Worth of Richard L Gabriel is at least $58.5 Thousand dollars as of 1 September 2020. Mr Gabriel owns over 4,000 units of Predictive Oncology stock worth over $56,126 and over the last 6 years he sold POAI stock worth over $0. In addition, he makes $2,333 as Sr. VP of R&D at Predictive Oncology.About Predictive Oncology (NASDAQ: POAI) The leading edge of a new frontier in drug discovery As a science-driven company on the leading edge of oncology drug discovery, Predictive Oncology offers an unrivaled suite of solutions for the biopharma industry. Through the integration of scientific rigor and machine learning, the company has developed the ability to … About us Read More » Instagram:https://instagram. tmcxx yieldrare quarters to look out forgig platformforex broker trading Oncology Pharma Inc () Stock Market info Recommendations: Buy or sell Oncology Pharma stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Oncology Pharma share forecasts, stock quote and buy / sell signals below.According to present data Oncology Pharma's ONPH shares and potentially its …The estimated Net Worth of Carl I. Schwartz is at least $1.17 Milion dollars as of 22 October 2020. Dr Schwartz owns over 640 units of Predictive Oncology stock worth over $741,217 and over the last 7 years he sold POAI stock worth over $544. In addition, he makes $433,000 as CEO & Director at Predictive Oncology. rfvtxgas and oil stocks Predictive Oncology’s revenue increased by 45% to $455,000 in the most recent quarter, but the company continues to produce substantial losses. Thus, this is a relatively high-risk, high-upside ...Overview Press Releases Events & Presentations Financials & Filings Stock Quote & Chart Corporate Governance Contact Us Stock Quote (POAI) NASDAQ CM: POAI $3.17 Oct 2, 2023 4:00 PM EDT Change 0 (0.00%) Volume 0 Today's Open -- Previous Close $3.17 Today's High $3.20 Today's Low $3.07 52 Week High $13.88 52 Week Low $2.47 Stock Chart best alternative to coinbase Find the latest Predictive Oncology Inc. (POAI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Find the latest Predictive Oncology Inc. (POAI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.